文献速递鼻科

美泊利单抗联合鼻窦手术对比单用美泊利单抗的优越获益:一项随机6个月试验结果

Superior Benefits of Combining Mepolizumab With Sinus Surgery Compared to Mepolizumab Alone: Results From a Randomised 6-Month Trial.
PubMed 文献 · Int Forum Allergy Rhinol · 2025-03-10

这项随机对照试验纳入58例伴2型炎症的慢性鼻窦炎伴鼻息肉患者,随机分为手术组与非手术组,所有患者每4周皮下注射100 mg美泊利单抗共6个月,手术组在首次注射后2周接受手术。结果显示两组SNOT-22评分在6个月后均显著改善,但组间差异未达统计学显著(p=0.055);鼻息肉评分6-8分的大息肉患者接受联合治疗后SNOT-22、ΔNPS、NCS降低更显著。

要点

  • 两组6个月后SNOT-22评分均显著改善(p<0.001),组间差异未达统计学显著(p=0.055)。
  • 鼻息肉评分6-8分患者中,联合手术组SNOT-22改善显著优于单用美泊利单抗组(p<0.05)。
  • 大息肉患者联合手术组ΔNPS(p<0.001)和NCS降低(p<0.001)更显著,VAS CRS改善p=0.074。

核心结论

  • 鼻息肉评分较大的患者在接受功能性内镜鼻窦手术联合美泊利单抗治疗后,生活质量(SNOT-22)改善及NPS、NCS、VAS CRS降低程度均优于单用美泊利单抗治疗者。

研究设计与样本

  • 随机对照试验,纳入58例伴2型炎症的慢性鼻窦炎伴鼻息肉患者,随机分为手术组与非手术组。
  • 所有患者接受100 mg美泊利单抗皮下注射,每4周一次,共6个月;手术组在首次注射后2周接受手术。
  • 基线及6个月时采用SNOT-22、VAS、NCS、嗅棒识别测试(16根)评估,并行鼻内镜检查评估鼻息肉评分(NPS)。

主要发现

  • 两组治疗6个月后SNOT-22评分均较基线显著改善(p<0.001),组间差异未达统计学显著(p=0.055)。
  • 鼻息肉评分6-8分的患者中,联合手术组SNOT-22评分改善显著优于单用美泊利单抗组(p<0.05)。
  • 鼻息肉评分6-8分的患者中,联合手术组ΔNPS(p<0.001)和NCS降低(p<0.001)均较单用美泊利单抗组更显著,VAS CRS改善p=0.074。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) significantly impacts patients' quality of life (QoL). Standard treatments include nasal irrigations, nasal steroids, systemic corticosteroids, and functional endoscopic sinus surgery (FESS). Uncontrolled severe CRSwNP treated with monoclonal antibodies (biologic drugs) gain better disease control, although some residual symptoms may persist. Combining biologic therapy with FESS could potentially reduce residual symptoms faster and for a longer period. Therefore, we aim to compare the effectiveness of combined FESS and biologic therapy against biologics alone in patients with severe CRSwNP. MATERIALS AND METHODS: This randomised controlled trial (RCT) enrolled 58 patients with CRSwNP and type 2 inflammation who were randomly assigned to FESS or non-FESS groups. All patients were treated with 100 mg of s.c. mepolizumab every 4 weeks for 6 months. Those in the FESS group underwent surgery 2 weeks after the first injection. Patients were assessed at baseline and after 6 months using the sino-nasal outcome test-22 (SNOT-22), visual analog scale (VAS), nasal congestion score (NCS), and the smell identification test (16 sticks). Clinical evaluations were performed using rhinoscopy to identify nasal polyp scores (NPS). RESULTS: Both treatment groups significantly improved in terms of their SNOT-22 scores after 6 months of treatment (p < 0.001). There were not significant differences between the two groups (p = 0.055). Patients with large NPS (6-8) improved significantly in terms of their SNOT-22 scores when they underwent combined treatment (FESS and mepolizumab) compared with s.c. mepolizumab alone (p < 0.05). They also exhibited improvements in ΔNPS (p < 0.001), VAS CRS (p = 0.074), and NCS reduction (p < 0.001) after undergoing combined treatment compared with those who had mepolizumab alone. CONCLUSION: Patients with large polyp scores experienced significant improvements in their QoL (SNOT-22) and reduced NPS, NCS, and VAS CRS more when polyp burden was reduced with FESS in association with mepolizumab treatment compared to those treated with mepolizumab alone.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Homøe AS, Aanæs K, Tidemandsen JE, et al. Superior Benefits of Combining Mepolizumab With Sinus Surgery Compared to Mepolizumab Alone: Results From a Randomised 6-Month Trial. Int Forum Allergy Rhinol. 2025. PMID: 40065601. doi:10.1002/alr.23562

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。